The following is a video that shows how OCB and Meridian IT worked together to extend the development of our Stage II bowel cancer risk stratification tool; ColoProg. It describes how OCB worked with Meridian IT to deploy IBM® PowerAI Vision running on IBM Power Systems™ servers. We were able to accelerate analysis of digital images of tumours to determine the risk of recurrence of colorectal cancer. The benefits include:
- More than 10x faster image analysis enabling Oxford Cancer Biomarkers to test many more patients at the same time
- Enabling new standards of care, enhancing patient outcomes and boosting efficiency
- Reduced time-to-market and accelerated scaling, enabling Oxford Cancer Biomarkers to take its offering internationally
https://ibm.ent.box.com/s/qd3bhtw30oitft4arwbcrqnpf5zhoue0
Contact
Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743